Home > Back to Publisher > Report Information

Novel Drug Targets and Strategies for Asthma and Chronic Obstructive Pulmonary Disease

Decision Resources
September 1, 2011
SKU: DECR6505077

Abstract Table of Contents Related Reports

Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory diseases that share many characteristics, such as breathlessness, coughing, and airway obstruction; these diseases are treated with many of the same or same types of therapies. Patients with severe corticosteroid-refractory asthma are desperate for novel treatment options, a need that creates opportunities for development of innovative therapies that target novel mechanisms of action. Opportunities are also available for COPD drugs that are disease modifying-that is, they can halt the decline in lung function and/or repair damaged lung tissue. These needs are prompting a competitive search for new types of drugs against novel targets.

Questions Answered in This Report:

Multiple treatment options are available for patients with asthma and COPD. How large are the current asthma and COPD markets? How will the size of these markets change in the future? What types of opportunities are available?
The majority of asthma patients benefit adequately from current therapies, but patients with severe refractory asthma need new options. What therapies are available for patients with severe refractory asthma? Which novel targets are under investigation for asthma drugs? Which compounds targeting these mechanisms are the most promising? Which innovators are developing asthma drugs against novel targets?
Current therapies for COPD are used primarily to address patients' symptoms; no disease-modifying drugs are available. What strategies are developers using to identify disease-modifying drugs and agents that target COPD-specific inflammation? Which novel targets are under investigation for COPD drugs? Which compounds targeting these mechanisms are most promising? Which innovators are developing COPD drugs against novel targets?
Asthma and COPD are heterogeneous diseases. What impact will heterogeneity have on drug development for asthma and COPD? How will heterogeneity impact business models in these fields?
The need for novel drugs against new targets and mechanisms of action provides opportunities for biotech and specialty pharma. Which companies have novel platforms for innovative respiratory drug development? What drugs are innovator companies developing? What corporate partnerships have these companies formed? What companies have been involved in M&As?

Scope:

Overview of asthma: Overview, market size and forecast, unmet needs, opportunities.
Novel targets and strategies for asthma: Mechanisms of action, inflammation, opportunities, novel targets.
Overview of COPD: Overview, market size and forecast, unmet needs, opportunities.
Novel targets and strategies for COPD: Mechanisms of action, inflammation, opportunities, novel targets.
Innovation company activity: Innovative biotech and specialty pharma companies, technology focus, partnerships, M&As.
Outlook for asthma and COPD: Changing business models, emerging therapies and strategies, genetic factors, heightened regulatory scrutiny, genetic influences, government-sponsored initiatives.
Primary data: Survey results of 51 pulmonologists and 54 primary-care physicians conducted by Decision Resources in July 2011.

Please note, the PDF e-mail from publisher version of this report is for a global site license.

Novel Drug Targets and Strategies for Asthma and Chronic Obstructive Pulmonary Disease

Share this report

Other tasks

Research Assistance

Related Markets

Drug Discovery Reports

Free Alert Me service